Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
Completed
Pfizer
Phase 3
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether mitoxantrone and prednisone are more
effective with or without prinomastat in treating patients with metastatic prostate cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of mitoxantrone and
prednisone with or without prinomastat in treating patients who have metastatic prostate
cancer that has not responded to hormone therapy.
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
Completed
Pfizer
Phase 3
RATIONALE: Prinomastat may stop the growth of non-small cell lung cancer by stopping blood
flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop
growing or die.
PURPOSE: Randomized phase III trial to determine the effectiveness of prinomastat plus
cisplatin and gemcitabine in treating patients who have metastatic or recurrent non-small
cell lung cancer.
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Completed
Pfizer
Phase 2
RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow
to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing
or die.
PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus
temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
